8-K: Turn Therapeutics Presents Promising GX-03 Data

Turn Therapeutics presented updated investor information highlighting positive interim results for its GX-03 drug candidate in treating moderate-to-severe Atopic Dermatitis and advancing its Onychomycosis program.

Summary

• Turn Therapeutics presented an investor presentation on June 3, 2026, detailing progress on its GX-03 drug candidate.
• GX-03 is a non-systemic, non-steroid topical therapy targeting IL-36 and downstream cytokines for inflammatory diseases, with an initial focus on Atopic Dermatitis (AD).
• The company reported zero adverse events in over 200,000 patients who have received GX-03, with FDA clearances for non-cytotoxic, non-sensitizing, and non-irritating claims.
• A Phase 2 Randomized Controlled Trial (RCT) for moderate to severe AD is underway, with topline results expected mid-2026.
• Interim analysis of the Phase 2 AD trial showed significant improvements in EASI (Eczema Area and Severity Index) scores, with a 79.43% mean percentage reduction at Week 4 and 77.22% at Week 8 for GX-03.
• The trial also demonstrated strong responder rates, with 59.3% achieving IGA 0 or 1 at Week 4 and 70.4% at Week 8.
• The company is optimizing the Phase 2 trial design to emphasize Week 4 endpoints, particularly EASI-75, and is preparing for a Type B FDA meeting.
• Turn Therapeutics also presented data for GX-03 in Onychomycosis (toenail fungus), indicating approximately 70% efficacy with once-daily application and 85% with twice-daily application in a Phase 2 equivalent study.
• The company anticipates initiating Phase 3 trials for Onychomycosis in 2027, with a planned launch in 2029.
• Financial highlights include approximately $18M in cash burned since inception, an estimated $55-60M R&D spend for Phase 3 trials, and cash balances of $11M as of March 31, 2026, providing runway into Q1 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development due to the strong interim efficacy and safety data for GX-03, particularly in Atopic Dermatitis, and the promising results in Onychomycosis, suggesting significant market potential.

Positives

• GX-03 demonstrates a favorable safety and tolerability profile with zero reported adverse events in over 200,000 patients.
• The Phase 2 AD trial interim analysis shows substantial efficacy, with a 79.43% EASI reduction at Week 4 and 77.22% at Week 8.
• High responder rates were observed in the AD trial, with 59.3% achieving IGA 0 or 1 at Week 4 and 70.4% at Week 8.
• GX-03 shows promising efficacy for Onychomycosis, with approximately 70% efficacy for once-daily application and 85% for twice-daily application.
• The company has a robust intellectual property portfolio with 17 issued patents and extensive patent families.
• Cash balance of $11M as of March 31, 2026, provides runway into Q1 2027, with additional debt/equity tranches available.
• FDA clearances for GX-03 include non-cytotoxic, non-sensitizing, and non-irritating claims.

Negatives

• The company has burned approximately $18M since inception and anticipates significant R&D spend ($55-60M) for Phase 3 trials.
• The current cash balance may not be sufficient to cover all future R&D and G&A expenses without additional capital raises.
• The Onychomycosis Phase 3 initiation is planned for 2027, with a launch in 2029, indicating a long development timeline.
• The company is still in the process of preparing a Type B meeting package with the FDA for GX-03 development optimization.

Risks

• Uncertainties in clinical development and obtaining regulatory approvals for GX-03.
• No guarantee that pipeline products will prove commercially successful.
• Reliance on third-party partnerships and manufacturers.
• Dependence on patent protections for PermaFusion technology.
• Ability to access adequate capital to fund ongoing operations and development.
• Industry competition and economic factors could impact development and commercialization.
• Regulatory challenges in bringing new therapies to market.

Future Outlook

The company is advancing its GX-03 program through Phase 2 trials for Atopic Dermatitis with topline results expected mid-2026, and is preparing for Phase 3 trials for Onychomycosis to commence in 2027, targeting a 2029 launch. Optimization of the AD trial design and engagement with the FDA are key near-term activities.

Management Comments

• "Favorable safety and tolerability profile is encouraging and supports the potential for GX-03 to become an important first-line treatment option."
• "GX-03 suppresses IL-36 release via targeted modulation of the epithelial microenvironment, blunting Th2 response."
• "GX-03 suppresses Il-31 signaling, blunting itch/scratch signal and continued barrier disruption."
• "GX-03 targets key upstream and downstream cytokines to stop the chronic inflammatory loop."

Industry Context

StockSavvy.ai notes that Turn Therapeutics is operating in the highly competitive and rapidly evolving dermatology and immunology space. The company's focus on non-systemic, precision immunomodulation therapies like GX-03 aligns with a broader industry trend towards targeted treatments with improved safety profiles compared to traditional steroids or systemic immunosuppressants. The development of novel drug delivery platforms, such as PermaFusion, is also a key area of innovation within the sector.

Comparison to Industry Standards

• The interim results for GX-03 in Atopic Dermatitis (AD) show a mean EASI percentage reduction of 79.43% at Week 4, which appears competitive when compared to pivotal trials for approved topical treatments for AD. For example, some approved JAK inhibitors and PDE4 inhibitors have shown significant efficacy, but often come with black-box warnings or side effects that GX-03 aims to avoid.
• The efficacy of GX-03 in Onychomycosis (70-85%) is presented as significantly higher than current approved topical onychomycosis products, which are cited as having 6-18% efficacy. This suggests a potential disruptive impact if these results are replicated in Phase 3.
• The company highlights that current topical steroids offer quick relief but can cause necrosis with consistent use, while biologics carry systemic burden and risks of immunosuppression. GX-03 aims to offer safe, rapid disease control without systemic exposure, positioning it favorably against these established treatment modalities.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical data and potential for future product launches, contingent on successful development and capital availability.
• Patients: Potential for improved treatment options with better efficacy and safety profiles for Atopic Dermatitis and Onychomycosis.
• Employees: Continued employment and growth opportunities tied to successful development and commercialization.
• Creditors: Potential for increased value of debt if the company achieves commercial success, but also risk associated with ongoing capital needs.

Next Steps

• Prepare and submit a Type B meeting package to the FDA to optimize the GX-03 development pathway.
• Continue enrollment in the Phase 2 Atopic Dermatitis trial.
• Analyze topline data from the Phase 2 AD trial expected mid-2026.
• Initiate Phase 3 trials for Onychomycosis in 2027.
• Continue to extend patent coverage for its technologies.

Key Dates

Recommendation

The strong interim clinical data for GX-03 in Atopic Dermatitis, coupled with promising efficacy in Onychomycosis and a favorable safety profile, presents a compelling investment opportunity. The company's robust IP and clear development path, despite significant capital requirements, suggest substantial upside potential if development milestones are met.

Keywords

Turn Therapeutics, GX-03, Atopic Dermatitis, Onychomycosis, Immunomodulation, Dermatology, Clinical Trial, FDA